eligibility_summary
Eligibility summary: Inclusion—Adults ≥18 with histologically confirmed follicular lymphoma grade 1–3a, ineligible for or refusing HSCT, measurable disease (≥1 lesion LD >1.5 cm and LPD ≥1.0 cm), life expectancy ≥12 weeks. Exclusion—Transformed DLBCL, CNS or leptomeningeal lymphoma, prior PI3Kδ/PI3K inhibitors (e.g., idelalisib) or BTK inhibitors (e.g., ibrutinib), pregnant or breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Withdrawn Phase Ib/III trial in relapsed/refractory follicular lymphoma testing: 1) Parsaclisib (oral small‑molecule PI3Kδ inhibitor/kinase inhibitor) + rituximab, 2) Parsaclisib + rituximab + lenalidomide. Mechanisms: Parsaclisib selectively inhibits PI3Kδ, a leukocyte-restricted isoform central to B‑cell receptor signaling, suppressing PI3K–AKT/mTOR pathway activity, malignant B‑cell survival/proliferation, and potentially Treg function in the microenvironment. Rituximab is an anti‑CD20 monoclonal antibody that depletes CD20+ B cells via ADCC, CDC, and apoptosis. Lenalidomide is an immunomodulatory drug (IMiD, cereblon modulator) that degrades Ikaros/Aiolos, boosting IL‑2, T‑ and NK‑cell activity, and has anti‑angiogenic/direct antitumor effects. Targets: CD20+ follicular B cells, BCR/PI3Kδ–AKT pathway, T and NK effector cells.